cyrilzakka/clinical-trials huggingface dataset:
Effect of Moxifloxacin Versus Gatifloxacin on Corneal Epithelium Following Pterygium Excision

The purpose of this study is to determine whether there is a difference in corneal epithelial healing rate and/or toxicity following pterygium excision, between eyes treated post-operatively by moxifloxacin(VIGAMOX)versus gatifloxacin (ZYMAR).


Eligibility Criteria:
Inclusion Criteria:

1. diagnosis of primary pterygium with a clinical indication for surgery
2. informed consent

Exclusion Criteria:

1. known allergic reaction to fluoroquinolones.
2. secondary\\recurrent pterygium or clinical suspected conjunctival tumor.
3. eye surgery in the last 6 months.
4. eye disorders: severe dry eye syndrome, ocular surface diseases, glaucoma, recurrent corneal erosions, chronic corneal diseases, after chemical burn.
5. low compliance.
6. pregnancy
The Effect of Social Media on Eating Behaviours

This project aims to explore how social media use, in particular food photography, influences eating behaviours. It will be approached through three methods - a correlational experience sampling method, an experimental experience sampling method, and an experimental laboratory method. This registration describes the experimental laboratory method.

This project aims to explore how social media use, in particular food photography, influences eating behaviours.

The research question will be approached using a combination of methods. The first is the experience sampling method, where data is gathered from participants as they are going about their day-to-day lives. This method comprises two sub-sections - a correlational study, and an experimental study. The second approach is the experimental laboratory method, where participants will be randomly assigned to different conditions while given the opportunity to eat. This registration describes the experimental laboratory method.

Upon arrival at the lab, participants will first be required to fill in some online questionnaires (e.g. demographic information, mood rating scales). They will then be randomised to one of two conditions - to engage in food photography, or to engage in non-food photography - while eating some food and completing some rating scales. These photos will be taken with the intention of sharing on social media. Participants will then fill in some more online questionnaires, before leaving the lab. After the session, the amount of food consumed by the participants will be weighed.

As a control, all participants will be required to come back to the lab for a second visit one week later, where they will all complete the same eating and rating task, but without any phone use.

The expected outcome of the project is to collectively evaluate the data from the various methods to conclude how social media use, and in particular the act of food photography, influences the various aspects of eating behaviours.

Eligibility Criteria:
Inclusion Criteria:

- Instagram user

Exclusion Criteria:

* Symptoms / history of any medical or psychiatric conditions
* Allergies to food products
* History of eating disorders
* BMI: \<18/ \>28
* Excessive exercise (≥ 5 times a week of self-reported exercise)
* Currently on a special diet or deliberating restricting caloric intake
* Currently on a weight loss program
Effect of Lidocaine/Dexamethasone on the Success of IANB

The purpose of this prospective, randomized, double-blind study was to compare the success rate of IAN block injection carried out with two cartridges of 2% lidocaine with 1:80000 epinephrine each combined with 0.2 ml dexamethasone versus two cartridges of 2% lidocaine with 1:80000 epinephrine each combined with 0.2 ml sterile distilled water for endodontic treatment of mandibular molars with symptomatic irreversible pulpitis.

Several investigations have been carried out to demonstrate the effect of dexamethasone added to local anesthetics in regional block injections. These investigations shown that the addition of dexamethasone to local anaesthetics may prolong the duration of anesthesia and also results in a faster onset. It is hypothesized that dexamethasone added to lidocaine may affect the success rate of inferior alveolar nerve block

Eligibility Criteria:
Inclusion Criteria:

* vital mandibular molar tooth
* diagnosis of symptomatic irreversible pulpitis

Exclusion Criteria:

* younger than 18 years old
* history of significant medical conditions
* allergies to local anesthetics or sulfites
* pregnancy
* taking any medications that might influence anesthetic assessment
* active sites of pathosis in area of injection
* inability to give informed consent
A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus

The main purpose of this study is to learn about the side effects of LY3502970 when given to Japanese participants with type 2 diabetes mellitus (T2DM). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last up to 24 weeks, inclusive of screening and will include 10 visits to the study center.


Eligibility Criteria:
Inclusion Criteria:

* Males and females not of childbearing potential
* Have type 2 diabetes mellitus (T2DM) diagnosed for at least 1 year
* Have glycated hemoglobin (HbA1c) value ≥ 7.0% and ≤ 10.0% for participants treated with diet and exercise or HbA1c ≥ 6.5% and ≤ 9.0% for participants who have washed out antidiabetic medications at screening
* Have type 2 diabetes controlled with diet and exercise alone or are stable on a single oral antidiabetic medication (OAM); either metformin, DPP-4 (dipeptidyl peptidase-4) inhibitor, or SGLT2 (sodium-glucose co-transporter-2) inhibitor within 3 months prior to screening. Participants must withdraw from their OAM treatment for at least 28 days prior to dosing.

Exclusion Criteria:

* Have type 1 diabetes mellitus or latent autoimmune diabetes in adults.
* Have uncontrolled diabetes defined as an episode of ketoacidosis or hyperosmolar state requiring hospitalization
* Have had an episode of severe hypoglycemia, as defined by the occurrence of neuroglycopenic symptoms requiring the assistance of another person for recovery or have a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms.
* Have a history of acute or chronic pancreatitis or fasting serum triglyceride level of \>500 milligram per deciliter (mg/dL).
* Have known liver disease, obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or have elevations in aminotransferases (alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\]) greater than 3× upper limit of normal (ULN).
Effect of Metformin on Early Pregnancy Loss in Pregnant Women With Polycystic Ovarian Syndrome

The aim of this work is to study the effect of metformin use for reducing early pregnancy loss in pregnant patients with Polycystic ovary syndrome (PCOS).

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age. PCOS produces symptoms in approximately 5 to 10% of women of reproductive age (12-45 years old) and is thought to be one of the leading causes of the female subfertility

* The aim of this work is to study the effect of metformin use for reducing early pregnancy loss in pregnant patients with PCOS
* Research question:

In pregnant women with PCOS, does metformin use decreases the rate of early pregnancy loss?

-Research hypothesis: In Pregnant women with PCOS, metformin may reduce the rate of early pregnancy loss.

Eligibility Criteria:
Inclusion Criteria:

* Age : 25 - 35.
* Pregnant patients in their 1st trimester with history of infertility due to PCOS confirmed by at least 2 of the following criteria ( Rotterdam Criteria )

  * At least twelve small follicles 2-9 mm in at least one ovary; diagnosed by ultra sound examination.
  * Symptoms or biochemical evidence of hyperandrogenism; diagnosed by examination and laboratory investigations.
  * Anovulation or oligo-ovulation with fewer than nine menstrual periods every 12 months : diagnosed by thorough history taking.
* Non diabetic patients who received metformin along with other ovulation-inducing drugs prior to pregnancy.

Exclusion Criteria:

* patients with other causes of infertility other than PCOS
* contraindications to metformin : liver impairment , renal failure.
* Patients with PCOS who didn't receive Metformin with drugs of induction of ovulation before pregnancy.
Is Omega-3 Fatty Acid Red Blood Cell (RBC) Saturation Product Dependent?

To demonstrate that RBC saturation of the Omega-3 fatty acids reaching cardioprotective levels as proven with the HS-Omega-3 Index test will be achieved most efficiently depending on a specific product utilized within this study.

To demonstrate that RBC saturation of the Omega-3 fatty acids reaching cardioprotective levels as proven with the HS-Omega-3 Index test will be achieved most efficiently depending on a specific product utilized within this study. The HS-Omega-3 Index is a new test that measures blood levels of the cardioprotective omega-3 fatty acids, EPA and DHA. RBS saturation is being measured to identify how much Omega 3 is in the blood.

Eligibility Criteria:
Inclusion Criteria:

* Willing and able to give written informed consent.
* Subject motivation and willingness to cooperate with the investigator by following the required medication regimen.
* Subject willingness and ability to return for all visits during the study.
* Must be willing to discontinue all use of Omega-3 supplementation 2 weeks prior to study participation.

Exclusion Criteria:

* Concurrent involvement in any other clinical trial involving an investigational drug or device.
* Compromised cognitive ability which may be expected to interfere with study compliance.
* Uncontrolled or poorly controlled systemic disease ot the presence of any significant illness that could, in the judgment of the investigator, jeopardize subject safety or interfere with the interpretation of the results of the study.
* Subjects must not eat more that 1 non-fried fish meal per week.
* Subjects must not have undergone any bariatric surgery or have a malabsorption disorder.
Mesenchymal Stem Cell Based Therapy for the Treatment of Osteogenesis Imperfecta

The purpose of this study is to determine the safety and effectiveness of five infusions of characterized HLA-identical MSC in non immunosuppressed children with Osteogenesis Imperfecta (OI).

The principal aim of this trial is to assess the safety of non-mutated HLA-identical Mesenchymal stem cell (MSC) transplantation for OI pediatric patients irrespective of treatment with biphosphonates. Since MSC are inherently non-immunogenic and do not elicit proliferation of allogeneic lymphocytes (in co-culture experiments), a cell therapy based on HLA-identical or histocompatible (at least 5 shared out of 6 HLA antigens) allogenic MSC may be accomplished without subjecting the patients to immunosuppressor treatment. Adverse secondary effects due to immunosuppressor treatment will be avoided using this strategy thus patients may benefit from two cellular infusions. The patients will be followed for 2 years post their fifth and last MSC infusion.

Eligibility Criteria:
Inclusion Criteria:

* Patient age: older than 6 months and younger than 12 years old.
* Patients with molecular confirmation of mutation in either COL1A1 or COL1A2 genes associated with OI (type III).
* Patients with HLA identical (that shared at least 5/6 antigens) siblings willing to donate bone marrow-MSCs.
* All patients that fulfil the inclusion criteria regardless of whether or not they are undergoing biphosphonate treatment.
* Patients whose parents or the legal guardians are willing to sign the consent forms to participate in this clinical trial.

Exclusion Criteria:

* Patient age: older than 12 years old
* Patients lacking confirmation of mutation in either COL1A1 or COL1A2 genes associated with severe deforming OI (type III).
* Other pathological subtypes of OI.
* Patients lacking of HLA identical (that shared at least 5/6 antigens) siblings willing to donate bone marrow-MSCs.
* Immunodeficiencies and any other malignancies.
* Participation in other clinical trial.
* Any medical or psychiatric condition that in the researcher´s opinion could affect the patient´s ability to complete the trial or hamper the participation in the trial.
* Patients whose parents or the legal guardians do not sign the consent forms
The Impact of Coagulation Disorders on the Diagnosis and Prognosis of Sepsis

The study was a retrospective, single-center clinical study. From all patients admitted to the emergency ICU during the period of 2013.1.1-2019.12.31, the investigators screened all patients who met the criteria of 1) ≤7 days from symptom onset to enrollment; 2) patients who also met the criteria of the presence of clinical infections and Sequential Organ Failure Assessment (SOFA) score ≥2; and 3) met the exclusion criteria, and retrospectively collected coagulation indices of the patients before anticoagulation with or without the use of heparin or low molecular heparin, and recorded the worst values of coagulation function of patients before heparin were recorded, and the organ function, inflammatory response, immune indexes, and conversion rate of severe disease were observed, so as to investigate the role of conventional coagulation indexes (FDP, D-dimer) and thromboelastography in the early diagnosis of septicemia patients and to indicate the prognosis.


Eligibility Criteria:
Inclusion Criteria:

* Time from clinical symptoms to admission ≤ 7 days；
* infection was diagnosed by clinician
* Systemic inflammatory response syndrome，Systemic inflammatory response syndrome was defined as the presence of 2 or more of the following: (1) temperature \<36℃or \>38℃, (2) heart rate \>90 beats per minute, (3) respiratory rate \>20 breaths per minute or PaCO2 \< 32 mm Hg, or (4) white blood cell count ≥12 000 cells/mm3 or≤4000 cells/mm

Exclusion Criteria:

* Pregnancy and lactation
* Have hematological diseases (including acute and chronic leukemia, hemolytic anemia, hemophilia, aplastic anemia, bone marrow fibrosis, congenital or acquired coagulation factor deficiency, etc.)
* Anticoagulant or antiplatelet drug treatment
* 24 hours after severe trauma or surgery
* Autoimmune diseases
* cirrhosis
* Malignant tumor patients with personal history or undergoing radiotherapy, chemotherapy and targeted treatment
Study of Personalized Dietary Intervention for the Control of Essential Hypertension

An ongoing case study of psoriasis, shows reproducibly that ingestion of hydrogenated fats, and some flavourant or sweetener compounds, leads to relapse of psoriasis, and secondary food intolerances, followed by remission over a couple of months (cpcpsoriasis.blogspot.com). Hence a personalized categorical food avoidance diet averts relapse and maintains remission of psoriasis, with side benefit on blood pressure and other metabolic parameters (J Hypertension 2012; 30: e-suppl 1, poster 158). Study hypothesis: this dietary approach would improve the control of essential hypertension. A randomized controlled clinical trial is proposed to compare this dietary approach with conventional DASH-type dietary counselling. 40 study participants will be randomly assigned to either conventional or interventional dietary counselling. They will be comprehensively monitored (including gene expression studies) for two years. Outcome criteria will include blood pressure, complications of hypertension, side-benefit on comorbidity, and requirement for antihypertensive drugs.


Eligibility Criteria:
Inclusion Criteria:

1. average blood pressure exceeds 160/100mm Hg (140/90 if additional vascular risk), regardless of whether on treatment
2. on one or two antihypertensive drugs AND average BP exceeds 140/90 (130/80 if additional risk)
3. on three or more antihypertensives, regardless of whether BP controlled
4. sufficiently literate to follow detailed dietary instructions
5. informed consent

Exclusion Criteria:

1. disabling complications of hypertension
2. secondary cause of hypertension
3. pregnancy
4. age less than 18 years
The Steno 780G Study

Treatment with insulin pumps and sensor-based glucose monitoring has proven superior to other treatment methods in type 1 diabetes. Still, the majority of people treated with insulin pumps and glucose sensors still does not meet the recommended sensor-based glycaemic targets. Automated insulin delivery systems, also known as closed-loop systems, have shown to improve TIR, TAR, and TBR compared with insulin pump and CGM systems that cannot automatically dose insulin.

The primary objective of the Steno 780G study is to test the effects of the MiniMed 780G system in persons with T1D treated with insulin pump and CGM/isCGM who are not meeting glycaemic targets.


Eligibility Criteria:
Inclusion Criteria:

* Age 18-75 years
* Type 1 diabetes ≥2 years.
* HbA1c \>=58 mmol/mol
* Insulin pump treatment ≥12 months
* CGM or isCGM use ≥6 months
* Novorapid use ≥1 week
* Carbohydrate counting and use of the insulin pump bolus calculator for most snacks and meals.
* Carbohydrate intake \>80 grams per day (assessed by review of intake recorded in the insulin pump during the 2 weeks prior to the screening visit)

Exclusion Criteria:

* Breast-feeding, pregnancy or planning to become pregnant.
* Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period or within 30 days prior to study start.
* Use of hybrid closed-loop systems
* Daily use of paracetamol (acetaminophen)
* Alcohol or drug abuse.
* Severe cardiac disease or retinopathy contraindicating HbA1c \<53 mmol/mol.
* Other concomitant medical or psychological condition that according to the investigator's assessment makes the person unsuitable for study participation.
* Lack of compliance with key study procedures at the discretion of the investigator.
* Unacceptable adverse events at the discretion of the investigator.
Branched Chain Amino Acid Plus Glucose Supplement Reduces Exercise-Induced Delayed Onset Muscle Soreness in College Females

The purpose of this study is to determine if a dietary supplement containing branched chain amino acids will reduce the muscle soreness that sometimes occurs in the days following exercise.

Supplementation with branched chain amino acids (BCAAs) has been used to stimulate muscle protein synthesis following exercise. The purpose of this study was to determine if supplementation with BCAAs in combination with glucose would reduce exercise-induced delayed onset muscle soreness (DOMS). Using a double-blind crossover design, 20 subjects (11 females, 9 males) were randomly assigned to either BCAA (n=10) or placebo (n=10) groups. Subjects performed a squatting exercise to elicit DOMS and rated their muscle soreness every 24 hours for four days following exercise while continuing to consume the BCAA or placebo. Following a three-week recovery period, subjects returned and received the alternate BCAA or placebo treatment, repeating the same exercise and DOMS rating protocol for the next four days. BCAA supplementation in female subjects resulted in a significant decrease in DOMS versus placebo at 24 hours following exercise (p = 0.018). No significant effect of BCAA supplementation versus placebo was noted in male subjects, nor when male and female results were analyzed together. This gender difference may be related to dose per body weight differences between male and female subjects.

Eligibility Criteria:
Inclusion Criteria:

* Men (n=9) and women (n=11) aged 18-25 who engaged in no more than one hour of light to moderate intensity physical activity per week were recruited from the Greater Burlington, Vermont area.

Exclusion Criteria:

* individuals who engaged in more than one hour per week of light to moderate physical activity
* had been involved in strict athletic competition or weight training in the past six months
* were pregnant or nursing, had a known muscular disease, diabetes mellitus, cardiovascular disease, respiratory disease, and/or were currently taking a protein-based dietary supplement
A Post Marketing Surveillance Study Of Doxazosin Mesylate GITS Among Filipino Patients With Benign Prostatic Hyperplasia (BPH)

This study aims to assess the safety, tolerability and efficacy of Doxazosin GITS in Filipino patients diagnosed with Benign Prostatic Hyperplasia (BPH) under the usual clinical care setting.

This is an open label study. All patients prescribed with Doxazosin GITS can be enrolled in this study.

Eligibility Criteria:
Inclusion Criteria:

* Subjects that will be included must be consistent with the approved label indication of Doxazosin mesylate GITS in the Philippines, which includes adult male diagnosed with BPH, and who are prescribed with Doxazosin mesylate GITS.

Exclusion Criteria:

* Subjects with condition that are contraindicated with Doxazosin mesylate GITS based on the approved labeling in the Philippines.
Substitution Heuristic on Proportional Tasks

The goal of this clinical trial is to test whether or not adults use a substitution heuristic when reasoning about proportions. The main question it aims to answer is:

Do adults use a substitution heuristic when judging non-symbolic proportions, leading them to answer an easier, yet incorrect question?

Researchers will compare performance at baseline with one of two conditions in order to see if forced behavioral changes can change performance on the task.

Participants will be asked to compare two images and judge which has the higher proportion of the target color. Each participant will also be assigned to one of two condition where they either receive a further incentive for correct selections or are required to use more time when making their calculations.


Eligibility Criteria:
Inclusion Criteria:

* Typically developing people within the target age range

Exclusion Criteria:

* Individuals with known developmental or cognitive disorders
* Participants must speak/read sufficient English to read and complete the informed consent document